FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	
-------------	------	-------	--

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response.	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Szekeres David Leslie					H	2. Issuer Name and Ticker or Trading Symbol HERON THERAPEUTICS, INC. /DE/ [HRTX]									all applic Directo Officer	or (give title		10% Owner Other (specify		
(Last) 4242 CA SUITE 2	MPUS PO	irst) INT COURT	(Middle)		07/	3. Date of Earliest Transaction (Month/Day/Year) 07/13/2021									EVP, Chief Operating Officer					
(Street) SAN DII (City)			92121 (Zip)		_ 4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)									lividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tab	le I - N	on-Deriv	vative	Sec	uriti	ies Ac	quire	l, Di	sposed o	of, or Be	nefic	ially	Owned	t				
1. Title of Security (Instr. 3)		Date	Date (Month/Day/Year) in		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4 a			and 5) Securiti Benefic Owned		es ially Following	Forn (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)		
Common Stock			04/30/	2021				J ⁽¹⁾	V	1,530	A	\$13.	8975	75 2,347			D			
Common	Stock	07/13/2021)21		M		1,250	A	(2)	3,597		D					
Common	Stock			07/13/	2021				F		433	D (3)	\$13	3.48	.48 3,164 D					
		Т	able II								posed of converti				wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	med on Date, Day/Year)	4. Transa Code (8)				6. Date Expirati (Month/	on Da		7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		De Se (Ir	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amou or Numb of Share	ber						
Restricted Stock Units	(2)	07/13/2021			M			1,250	(4)		(4)	Common Stock	1,25	50	\$0.00	16,250)	D		

Explanation of Responses:

- 1. Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2021.
- 2. Restricted stock units convert into common stock on a one-for-one basis.
- 3. Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.
- $4. \ The \ restricted \ stock \ units \ vest \ in \ 16 \ equal \ quarterly \ installments \ beginning \ three \ months \ after \ the \ date \ of \ grant \ (10/13/2020).$

Remarks:

/s/ Lisa Peraza Attorney-in-fact 07/15/2021 for David Szekeres

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.